PHP240 - HEALTH TECHNOLOGY ASSESSMENTS OF BEVACIZUMAB BIOSIMILARS- COULD A DEMONSTRATION OF COST-EFFECTIVENESS CHANGE THE RECOMMENDATION FOR REIMBURSEMENT VERSUS THE ORIGINATOR?
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1134
https://www.valueinhealthjournal.com/article/S1098-3015(18)34436-X/fulltext
Title :
PHP240 - HEALTH TECHNOLOGY ASSESSMENTS OF BEVACIZUMAB BIOSIMILARS- COULD A DEMONSTRATION OF COST-EFFECTIVENESS CHANGE THE RECOMMENDATION FOR REIMBURSEMENT VERSUS THE ORIGINATOR?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34436-X&doi=10.1016/j.jval.2018.09.1134
First page :
Section Title :
Open access? :
No
Section Order :
528